Magic™ Human OX40L (TNFSF4) Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The application of TNFSF4 (tumor necrosis factor superfamily member 4) has been studied in various fields. In medicine, TNFSF4 has been investigated as a potential prognostic biomarker in hepatocellular carcinoma (HCC). The gene DHRS1, a member of the short-chain dehydrogenase/reductase superfamily, has been identified as a predictor of HCC. DHRS1-associated immunomodulators have been found to strongly correlate with survival in HCC patients. A risk score based on these immunomodulators has been developed and shown to be an independent indicator of HCC prognosis. TNFSF4 has also been implicated in osteosarcoma, where it influences the prognostic and immune microenvironment of the disease. Ferroptosis-related long non-coding RNAs (FRLncs) associated with TNFSF4 have been identified as potential prognostic markers in osteosarcoma. In addition, TNFSF4 has been found to be activated in sclerotic-type cutaneous chronic graft-versus-host disease, a complication of allogeneic hematopoietic stem cell transplantation. The disease exhibits strong T helper 1 (Th1) skewing and upregulation of TNFSF4 and other related cytokines. Furthermore, TNFSF4 has been studied in breast cancer, where it is associated with ferroptosis-related genes. A prognostic model based on these genes has been developed, and TNFSF4 has been identified as a potential therapeutic target. Overall, TNFSF4 has shown promise as a prognostic biomarker and therapeutic target in various diseases.